Special and award session
Program at a glance
Scientific Program
Social Program
Education Course
Plenary lectures Main sympsia Research group and committee session Special and award session Corporate symposia Video on demand session Oral presentations
Plenary lectures Main sympsia Research group and committee session Special and award session Corporate symposia Video on demand session Oral presentations
| SP1 VERTIS CV VERTIGO in SGLT-2 inhibitor Era: All SGLT2i are same? |
Friday 18 September 14:00~16:00 Channel C Chairman : Jeong Hyun Park, Byung-Joon Kim |
Overview |
|---|---|---|
| Since the EMPA-REG study was announced, the benefits of SGLT-2 inhibitors for cardiovascular disease have had a ripple effect that could shake the existing paradigm of diabetes treatment. The SGLT-2 inhibitor class showed excellent benefits in cardiovascular disease, especially heart failure but it showed different results for other atherosclerotic cardiovascular diseases (ASCVD). Thus, there was controversy over whether the protective effect of each SGLT-2 inhibitors on ASCVD was consistent. Furthermore, the VERTIS-CV study presented in this year further confuses the physicians with unexpected results. In this session, Prof. Jeong Hyun Park, the professor from Inje University will present the overview of the VERTIS-CV trial. Two distinguished professors, Young Min Cho from Seoul National University and Gwanpyo Koh from Jeju National University will have a debate about the similarities and differences among the SGLT-2 inhibitors. This session will help to clinicians who want to provide the latest evidence and knowledge in the clinical practice. | ||
|
SP1-1VERTIS-CV Study - how can we interpret the results? | |
|
SP1-2ALL SGLT2 inhibitor are same - pros | |
|
SP1-3ALL SGLT2 inhibitor are same - cons | |
| SP2 Precision medicine Precision medicine in diabetes |
Saturday 19 September 15:50-17:50 Channel C Chairman: Tae Keun Oh, Sangah Chang |
Overview |
|---|---|---|
| Diabetes is one of the major global threats and many countries have been trying to cut down diabetes-related health burdens. This session entitled as Efforts for the prevention of diabetes and its complications was designed to deliver several ongoing projects to prevent diabetes epidemics as well as to integrate the diverse health records for establishing the most efficient way to combat against diabetes. This session will be a good chance to understand the current status in the field of diabetes prevention and standardization of health-related data. | ||
|
SP2-1Making AI meaningful in diabetes management | |
|
SP2-2Mission and vision of the all of us researcher workbench | |
| SP3 AI drug target AI-based novel drug target discovery |
15:50~17:50 / Saturday 19 September Channel D Chairman: Cheol Soo Choi, Eun Gyoung Hong |
Overview |
|---|---|---|
| This session, AI-based novel drug target discovery, is organized to introduce new advancements in drug target discovery based on Artificial Intelligence (AI) technologies. Currently, AI is being widely used in various stages of drug R&D, particularly such as drug design, drug repurposing, and recruiting patients for clinical trials. However, the application of AI technologies has been relatively limited in identifying novel drug targets, and there are vast unmet medical and pharmaceutical needs in this field. This session will introduce new AI-based, systematic approaches for the discovery of novel drug targets. | ||
|
SP3-1An artificial intelligence-aided interactive platform for explainable target identification | |
|
SP3-2Application of machine learning in target discovery | |
|
SP3-3AI-based systematic target discovery for metabolic diseases | |
| AW1 Sulwon lecture | 12:30~12:50 / Friday 18 September Channel A Chairman: Kun Ho Yoon |
Overview |
|---|---|---|
| Every year, in order to inspire Dr. Eung-Jin Kim's will to stimulate research desire in the field of diabetes and to encourage academic activities, Sulwon Academic Award is awarded to researchers who have made outstanding achievements in research and development of diabetes. This year, Prof. Young-Bum Kim from Harvard University was selected as the recipient of the Sulwon Academic Award in recognition of his achievements in diabetes research. | ||
|
AW1 Control of fuel homeostasis by Rho-kinase | |
| AW2 Young investigator award lecture | 12:10~12:30 / Saturday 19 September Channel A Chairman: Kun Ho Yoon |
Overview |
|---|---|---|
| In order to inspire young researchers to promote research in the field of diabetes and to encourage academic activities, KDA awards Young Investigators' Award (YIA) every year to young researchers under the age of 45 who have made outstanding achievements in research and development of diabetes. This year, Assistant Professon Nam-Hoon Kim from Korea University was selected as the recipient of YIA in recognition of his achievements in diabetes research. | ||
|
AW2It`s time to build high level of real-world evidence in diabetes and metabolism research | |
